On November 30, 2022 Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, reported that Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 11:00 am ET (Press release, Elevation Oncology, NOV 30, 2022, View Source;utm_medium=rss&utm_campaign=elevation-oncology-to-participate-at-the-jmp-securities-hematology-and-oncology-summit [SID1234624598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and replay of this event will be available on the Events page of the Company’s Investor Relations website at View Source

On December 1, 2022 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10 (Press release, Eisai, NOV 30, 2022, View Source [SID1234624597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:

– Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.

– Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.

"We continue to relentlessly pursue research that provides useful insights for people living with breast cancer," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "A big part of this commitment is the ongoing sharing of our preclinical and clinical data with eribulin."

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Eisai presentations at the 2022 SABCS are as follows:

Product
Abstract No. Abstract name and scheduled presentation date and time
(Central Standard Time)
Eribulin
Program #: P1-03-02
Efficacy of eribulin mesylate in HER2-low and HER2-0 metastatic breast cancer (MBC): Results from an analysis of two phase 3 studies

Poster Session | December 6 (Tues), 5:00-7:00PM
Eribulin
Program #: P1-03-03
Real-world treatment patterns and clinical outcomes in patients treated with Eribulin after prior PI3K inhibitor therapy for metastatic breast cancer

Poster Session | December 6 (Tues), 5:00-7:00PM
Eribulin
Program #: P3-07-03
Anti-tumor activity of a liposomal formulation of Eribulin compared with the same dose of Eribulin in patient-derived breast cancer xenografts

Poster Session | December 7 (Wed), 5:00-7:00PM
Eribulin
Program #: P4-07-19
Eribulin enhances STING-dependent induction of type I interferons in immune and triple-negative breast cancer cells

Poster Session | December 8 (Thurs), 7:00-9:00AM
Eribulin
Program #: P6-01-23
Role of tumor infiltrating lymphocytes and PD-L1 expression in the response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial

Poster Session | December 9 (Fri), 7:00-9:00AM

On November 30, 2022 CTI BioPharma Corp. (NASDAQ: CTIC) reported that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET (Press release, CTI BioPharma, NOV 30, 2022, View Source [SID1234624596]). The conference will be held in a virtual meeting format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Event: JMP Securities Hematology and Oncology Summit
Date: Tuesday, December 6, 2022
Time: 3:00 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com.

On November 30, 2022 Century Therapeutics presented its Corporate Overview (Presentation, Century Therapeutics, NOV 30, 2022, View Source [SID1234624595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 30, 2022 BioNTech SE (Nasdaq: BNTX, "BioNTech") and Ryvu Therapeutics S.A. (Warsaw Stock Exchange: RVU, "Ryvu"), a clinical-stage company developing oncology therapeutics reported that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING agonist portfolio as standalone small molecules (Press release, BioNTech, NOV 30, 2022, View Source [SID1234624593]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations. In addition, BioNTech and Ryvu will jointly undertake drug discovery and research projects to develop multiple small molecule programs directed at exclusive targets selected by BioNTech, primarily focused on immune modulation within oncology, with potential applications in other disease areas. BioNTech has the option to license global development and commercialization rights to these programs at the development candidate stage.

"Small molecules targeting novel immune signaling pathways have a great potential to increase the efficacy of cancer immunotherapies," said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. "The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules."

"Ryvu is excited to bring its expertise in immuno-oncology to work with a global leader in the development of immunomodulatory targeted therapies," said Paweł Przewięźlikowski, Chief Executive Officer, Ryvu. "BioNTech’s expertise in immunomodulatory mechanisms is a great match for Ryvu’s platform, and we fully expect to develop differentiated, therapeutically effective and safe molecules with our combined expertise."

Under the terms of the agreement, BioNTech will pay Ryvu an upfront fee of €20 million in exchange for certain rights to Ryvu’s STING agonist portfolio as standalone small molecules and for certain rights and options to license multiple small molecule programs as part of a multi-target research collaboration. In addition, BioNTech has committed to make an equity investment of €20 million.

BioNTech will fund all discovery, research and development activities, including Ryvu’s discovery and research activities under the multi-target research collaboration. Ryvu will be eligible to receive success-based development, regulatory and commercialization milestone payments, as well as low single-digit royalties on the annual net sales of any products that are successfully commercialized under the collaboration.

About STING Agonists
The STING pathway plays a critical role during infections and autoimmune disease, but also is one of the key innate immunity pathways responsible for antitumor immunity, as it’s activated by tumor derived DNA. Therefore, therapeutic targeting of STING is a potential new target for cancer therapies as it leads to potent activation of innate and adaptive immune response. In preclinical studies, as presented at SITC (Free SITC Whitepaper) 2021 and AACR (Free AACR Whitepaper) 2021, Ryvu’s STING agonists activated all STING haplotypes and led to high activation of proinflammatory cytokine production and long-lasting immune responses after systemic administration in vivo.